Releases
If you would like to automatically receive our releases by e-mail, it takes just a moment to sign up for our subscription service.
Â
Latest releases from Lundbeck.
May 15, 2008
Share Buyback in H. Lundbeck A/S
Acting on its authorization to acquire up to 10% of its shares, Lundbeck's Supervisory Board has resolved to initiate a share buyback program. Under the program Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005. The buyback program is expected to be completed by the end of 2008.
Acting on its authorization to acquire up to 10% of its shares, Lundbeck's Supervisory Board has resolved to initiate a share buyback program. Under the program Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005. The buyback program is expected to be completed by the end of 2008.
May 13, 2008
Circadin® launch rollout starts with the launch of the product in the important German market
Lundbeck today announced the launch of Circadin® for insomnia in Germany. Circadin® was approved by the European Commission on 29 June 2007, and Lundbeck expects to launch the product in another 14 markets during 2008.
Lundbeck today announced the launch of Circadin® for insomnia in Germany. Circadin® was approved by the European Commission on 29 June 2007, and Lundbeck expects to launch the product in another 14 markets during 2008.
May 7, 2008
Interim report for the first quarter of 2008 - strong growth in sales and profits
Lundbeck's interim report for the first quarter of 2008 shows continuing strong growth in consolidated revenue distributed on the company's new products as well as on the regions. Lundbeck retains its financial forecasts for revenue and profit from operations which the company announced in connection with the release of its annual report for 2007.
Lundbeck's interim report for the first quarter of 2008 shows continuing strong growth in consolidated revenue distributed on the company's new products as well as on the regions. Lundbeck retains its financial forecasts for revenue and profit from operations which the company announced in connection with the release of its annual report for 2007.
May 2, 2008
Share Buyback in H. Lundbeck A/S
Acting on its authorization to acquire up to 10% of its shares, Lundbeck's Supervisory Board has resolved to initiate a share buyback program. Under the program Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005. The buyback program is expected to be completed by the end of 2008.
Acting on its authorization to acquire up to 10% of its shares, Lundbeck's Supervisory Board has resolved to initiate a share buyback program. Under the program Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005. The buyback program is expected to be completed by the end of 2008.
April 30, 2008
Lundbeck expands geographical rights for Circadin®
H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. today announced that Lundbeck has obtained expanded exclusive rights to commercialize Circadin® in Asia, Latin America and other major markets such as Australia and Turkey. Following regulatory filing and approval Lundbeck expects to market Circadin® in the first markets outside of Europe in 2009.
H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. today announced that Lundbeck has obtained expanded exclusive rights to commercialize Circadin® in Asia, Latin America and other major markets such as Australia and Turkey. Following regulatory filing and approval Lundbeck expects to market Circadin® in the first markets outside of Europe in 2009.
Go to top
H. Lundbeck A/S
Ottiliavej 9
DK-2500 Copenhagen Valby
Ottiliavej 9
DK-2500 Copenhagen Valby
Tel +45 36 30 13 11
Fax +45 36 30 19 40
Fax +45 36 30 19 40
The specialist in psychiatry and pioneer in neurology
Disclaimer & Privacy statement
Disclaimer & Privacy statement